Skip to main content
Log in

Is there a future for PET in oncology?

  • Editorial
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Ghossein RA, Rosai J. Polymerase chain reaction in the detection of micrometastases and circulating tumour cells.Cancer 1996; 78: 10–16.

    Google Scholar 

  2. Chen XQ, et al. Microsatellite alterations in plasma DNA of small cell lung cancer patients.Nature Med 1996; 2: 1033–1035.

    Google Scholar 

  3. Price P, Jones T. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy?Eur J Cancer 1995; 31A: 1924–1927.

    Google Scholar 

  4. Price P, Harte R, Tisley D, Matthews J. The use of radiolabelled anticancer drugs in phase I/II clinical trials and the assessment of the therapeutic efficacy of new agents using PET. In: Comar D, ed.PET for drug development and evaluation. London: Kluwer Academic; 1995: 301–326.

    Google Scholar 

  5. Jones T. The role of PET within the spectrum of medical imaging.Eur J Nucl Med 1996; 23: 331–335.

    Google Scholar 

  6. Jones T. The imaging science of positron emission tomography.Eur J Nucl Med 1996; 23: 807–813.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Price, P. Is there a future for PET in oncology?. Eur J Nucl Med 24, 587–589 (1997). https://doi.org/10.1007/BF00841393

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00841393

Navigation